drugset / Trial / NCT03458221
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
Phase 2/3
Recruiting
148 enrolled
Gynaecologisch Oncologisch Centrum Zuid
Erasmus Medical Center · collabEurofins · collabInnoSIGN · collabMaastricht University Medical Center · collabRadboud University Medical Center · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) activity in recurrent ovarian cancer patients using a novel mRNA-based assay. Existing targeted drugs with tolerable toxicity profiles are used to investigate the therapeutic value beyond their approved indication, which are deemed beneficial in the select group of patients with a relevant predominantly active functional STP, in order to improve survival and maintain quality of life.
Timeline
- Start
- 2023-01-31
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | 150 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Itraconazole | Small molecule | 300 mg | Oral |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |